Insight

Reference

·

Supporting source

Thailand Precision Medicine Operator Concentration — Top 6 Share

~70% of FY2026 spend held by six operators

As ofFY2026·Sources4·Supporting

BDMS Precision Oncology Centre (estimated 22% share), Bumrungrad Horizon Center (18%), BNH Hospital cancer centre (9%), Bangkok Genomics (8%), Vejthani international cancer centre (7%), and Asia Genomics Thailand plus Geneus DNA (6% each) together hold roughly 70% of estimated 2026 Thai precision-medicine spend. Quantum Tech (3%) and iBiotech (2%) plus pharma-paired CDx labs (Roche FoundationOne, Novartis/AstraZeneca/MSD access programmes) and a long tail of independent precision-oncology and PGx boutiques (aggregate 10%) make up the balance. Concentration is structurally healthy because reimbursement scaling and lab-capacity expansion both reward the larger operators with NHSO bundle access, capacity headroom, and medical-tourism distribution.

Download CSV ↓Compare plans →

Figure in context

BDMS Precision Oncology Centre (estimated 22% share), Bumrungrad Horizon Center (18%), BNH Hospital cancer centre (9%), Bangkok Genomics (8%), Vejthani international cancer centre (7%), and Asia Genomics Thailand plus Geneus DNA (6% each) together hold roughly 70% of estimated 2026 Thai precision-medicine spend. Quantum Tech (3%) and iBiotech (2%) plus pharma-paired CDx labs (Roche FoundationOne, Novartis/AstraZeneca/MSD access programmes) and a long tail of independent precision-oncology and PGx boutiques (aggregate 10%) make up the balance. Concentration is structurally healthy because reimbursement scaling and lab-capacity expansion both reward the larger operators with NHSO bundle access, capacity headroom, and medical-tourism distribution.

BDMS Precision Oncology Centre (estimated 22% share), Bumrungrad Horizon Center (18%), BNH Hospital cancer centre (9%), Bangkok Genomics (8%), Vejthani international cancer centre (7%), and Asia Genomics Thailand plus Geneus DNA (6% each) together hold roughly 70% of estimated 2026 Thai precision-medicine spend. Quantum Tech (3%) and iBiotech (2%) plus pharma-paired CDx labs (Roche FoundationOne, Novartis/AstraZeneca/MSD access programmes) and a long tail of independent precision-oncology and PGx boutiques (aggregate 10%) make up the balance. Concentration is structurally healthy because reimbursement scaling and lab-capacity expansion both reward the larger operators with NHSO bundle access, capacity headroom, and medical-tourism distribution.

Time scope

FY2026

Source basis

Supporting source

Interpretation notes

What this tells you

BDMS Precision Oncology Centre (estimated 22% share), Bumrungrad Horizon Center (18%), BNH Hospital cancer centre (9%), Bangkok Genomics (8%), Vejthani international cancer centre (7%), and Asia Genomics Thailand plus Geneus DNA (6% each) together hold roughly 70% of estimated 2026 Thai precision-medicine spend. Quantum Tech (3%) and iBiotech (2%) plus pharma-paired CDx labs (Roche FoundationOne, Novartis/AstraZeneca/MSD access programmes) and a long tail of independent precision-oncology and PGx boutiques (aggregate 10%) make up the balance. Concentration is structurally healthy because reimbursement scaling and lab-capacity expansion both reward the larger operators with NHSO bundle access, capacity headroom, and medical-tourism distribution.

What not to do with it

Use the linked report for interpretation and keep basis differences explicit.

Related figures

Adjacent numbers that add context without drowning the value.

Projection to 2027
~THB 12-19B (base ~THB 15B)

Thailand Precision Medicine Market Size — 2027 Projection

NHSO NLEM planning documents, Thai FDA NGS CDx framework draft, lab operator filings, hospital programme disclosures, Insight Research triangulation

Milestone target 2026
50,000 whole-genome and 200,000 array samples

Genome Thailand Cohort Size — 2026 Milestone

DMSc Genome Thailand programme documents, NIH-DMSc, MoPH

FY2026-2027 bundle inclusion phase
4-8 priority panels (HER2, EGFR, BRCA, KRAS, ALK, PD-L1)

NHSO Priority CDx Panels Added to Oncology Bundles — FY2026-2027

NHSO National List of Essential Medicines planning documents, NHSO public consultations, hospital partner disclosures

FY2026
~THB 80,000-180,000 per package

Thailand Hospital-Integrated Personalised Cancer Package ASP

BDMS, Bumrungrad, BNH, Vejthani programme disclosures, Insight Research triangulation

FY2026
CDx 48% / PGx 22% / liquid biopsy 18% / PRS 12%

Thailand Precision Medicine Test-Type Mix — 2026 Estimate

Lab operator filings, hospital programme disclosures, NHSO planning documents, Insight Research triangulation

FY2026
~THB 6,000-9,000 per sample (COGS)

Thailand Clinical NGS Oncology Panel Cost-of-Goods (50-gene panel)

Lab operator filings, Asia Genomics, Quantum Tech), reagent supplier benchmarks, Insight Research triangulation

Report context

Thailand Precision Medicine & Genomics 2027 Market Intelligence

Thailand's precision-medicine layer (companion diagnostics, pharmacogenomics, liquid biopsy, polygenic risk scores) is moving out of research-only mode and into clinical reimbursement by 2027. The catalyst stack is unusually concentrated: Genome Thailand reaches 50,000 whole-genome and 200,000 array samples through 2026, NHSO Universal Coverage adds priority CDx panels into oncology bundles, BDMS, Bumrungrad, BNH, Vejthani build personalised treatment packages for medical-tourism patients, and lab capacity at Bangkok Genomics, Asia Genomics, Geneus DNA, Quantum Tech, iBiotech scales four to six times. Roche, AstraZeneca, MSD, Novartis pair launches with CDx labs while the Thai FDA finalises an NGS CDx framework. Our 2027 read: THB 12-19B market versus THB 3-5B in 2024, with six operators capturing more than 70% share and medical-tourism patients driving 35-50% of revenue.

Open report →

Atlas actors in this figure's reports

Profiles covered in the report that cite this number.

Bangkok Dusit Medical Services

Thailand's largest listed hospital group — 50+ hospitals across six brand families; >THB 110B FY2024 revenue.

Bumrungrad Hospital

Thailand's medical-tourism flagship — first Asian hospital JCI-accredited (2002); >60% international-patient revenue mix.

Novartis Thailand

Swiss-parent MNC specialty Thai subsidiary; oncology, cardiovascular, biosimilar; ~6% Thai market value share.

Roche Thailand

Swiss-parent MNC specialty Thai subsidiary; oncology, biologics, diagnostics; ~5% Thai market value share.

Vejthani Hospital

Bangkok private hospital known for international patient services

Thailand Precision Medicine Operator Concentration — Top 6 Share · Insight